Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | B3GNT2 | Q9NY97 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7651382 | 0.89 | BACE1 (0.42) | BACE1PARP1KDM4EALDH1A1GAA | |
| SCHEMBL7684161 | 0.83 | SLC22A12 (0.36) | SLC22A12PARP1KDM4ERECQLCSNK2A1 | |
| SCHEMBL4261343 | 0.73 | SLC22A12 (0.60) | SLC22A12PARP1KDM4EALDH1A1GAA | |
| SCHEMBL7651372 | 0.73 | ALDH1A1 (0.37) | PARP1KDM4ECSNK2A1ALDH1A1GAA | |
| SCHEMBL7428046 | 0.72 | BACE1 (0.45) | BACE1XDH | |
| SCHEMBL23559591 | 0.70 | HCAR3 (0.46) | SLC22A12KDM4EALDH1A1GAAHPGD | |
| Trifluoroacetic Acid SCHEMBL7663616 | 0.69 | BACE1 (0.62) | BACE1XDHALDH1A1 | |
| SCHEMBL7431955 | 0.68 | BACE1 (0.41) | BACE1XDH | |
| SCHEMBL7428009 | 0.67 | BACE1 (0.45) | BACE1XDHALDH1A1HSD17B10 | |
| SCHEMBL17785249 | 0.66 | HCAR3 (0.47) | SLC22A12PARP1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6489333-B2 | HETEROCYCLIC COMPOUNDS CONTAINING A GUANIDINE MIMIC, FOR INHIBITION OF CELL ADHESION, TREATMENT OF ANGIOGENESIS DISORDERS, INFLAMMATION, CANCER METASTASIS, DIABETIC RETINOPATHY, THROMBOSIS, RESTENOSIS, MACULAR DEGENERATION | BRISTOL - MEYERS SQUIBB PHARMA COMPANY | 2002-12-03 | — | — | US | disclosed |
| US-20010044535-A1 | Integrin antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2001-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044535-A1 | Integrin antagonists | ITGB3, VCAM1, ITGB2 | BACE1 1375/4885SLC22A12 4004/4885PARP1 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.